Analysis of industry assets newly into human trials reveals three Car-T therapies and some familiar targets.

The first case reports with the group’s lead Car-T therapy, plus talk of autoimmune diseases and diabetes, prompt a 39% share price surge.

Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.

Ambrx’s PSMA-targeting ADC generated puzzling data at ESMO, but J&J has seen enough to launch a premium-priced buyout.